Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other mRNAs with partial seed complementarity refers to a broad class of unintended genetic targets that are silenced by small interfering RNAs (siRNAs) or microRNAs (miRNAs) through sequence-specific interactions. This phenomenon, often termed "seed-mediated off-target effects," occurs when the seed region of the oligonucleotide guide strand (nucleotides 2-8) binds to complementary sequences in the 3' untranslated regions (UTRs) of non-target mRNAs (Jackson et al., 2003, Nature Biotechnology). Once bound, these off-target mRNAs are processed by the RNA-induced silencing complex (RISC), resulting in mRNA degradation or the inhibition of protein translation. In the field of oligonucleotide therapeutics, these interactions are a primary source of sequence-specific toxicity and can lead to adverse clinical outcomes such as hepatotoxicity (Janas et al., 2018, Nature Communications). To minimize these risks, drug developers employ chemical modifications, such as 2'-O-methyl substitutions at the second nucleotide of the guide strand, to destabilize off-target binding while maintaining on-target potency. Understanding and predicting these interactions through bioinformatic screening is a critical component of the safety assessment for any RNA-based therapeutic (Setten et al., 2019, Nature Reviews Drug Discovery).
The guide strand of an siRNA or miRNA incorporates into the RNA-induced silencing complex (RISC) and utilizes its "seed region" (nucleotides 2-8) to bind via partial complementarity to the 3' untranslated regions (UTRs) of unintended mRNAs, leading to their degradation or translational repression (Birmingham et al., 2006, Nature Methods; Jackson et al., 2003, Nature Biotechnology).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other mRNAs with partial seed complementarity.